AstraZeneca and Bristol Myers Squibb are reportedly in discussions about a possible merger, according to the Financial Times, with coverage appearing in Seeking Alpha and Investing.com. The reports indicate that the companies are exploring whether a combination would be feasible, but they do not provide confirmed details on deal terms, valuation, or timing. Neither outlet’s provided material states that talks have progressed to an agreement, nor do they specify whether regulators or shareholders are already engaged. The coverage also does not outline what specific corporate structures, assets, or business lines would be involved. As presented, the information is preliminary and framed as ongoing talks rather than finalized plans. Further reporting would be needed to confirm whether discussions lead to a formal transaction and how any such merger would be assessed under competition and other applicable rules. The companies involved have not been described in the provided excerpts as publicly confirming the discussions.